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http://dx.doi.org/10.1016/j.stemcr.2016.07.012SUMMARYThe development of dengue antivirals and vaccine has been hampered by the incomplete understanding of molecular mechanisms of
dengue virus (DENV) infection and pathology, partly due to the limited suitable cell culture or animal models that can capture the
comprehensive cellular changes induced by DENV. In this study, we differentiated human pluripotent stem cells (hPSCs) into hepato-
cytes, one of the target cells of DENV, to investigate various aspects of DENV-hepatocyte interaction. hPSC-derived hepatocyte-like cells
(HLCs) supported persistent and productive DENV infection. The activation of interferon pathways by DENV protected bystander cells
from infection and protected the infected cells from massive apoptosis. Furthermore, DENV infection activated the NF-kB pathway,
which led to production of proinflammatory cytokines and downregulated many liver-specific genes such as albumin and coagulation
factor V. Our study demonstrates the utility of hPSC-derived hepatocytes as an in vitro model for DENV infection and reveals important
aspects of DENV-host interactions.INTRODUCTION
Dengue is emerging as one of the most widespread vector-
borne infectious diseases in humans. A recent large-scale
mapping of global dengue distribution estimates 390
million dengue infections per year worldwide (Bhatt et al.,
2013). The pathogenic agent dengue virus (DENV) is a
member of the Flaviviridae, a family of positive-strand
RNA viruses that include many additional important hu-
manpathogens such asWestNile virus andhepatitis Cvirus
(HCV). Infections of humans by DENV cause dengue fever
and the more severe dengue diseases, dengue hemorrhagic
fever (DHF) anddengue shock syndrome (DSS).DHF is char-
acterized by increased vascular permeability and hemor-
rhagic manifestations, and may progress to the life-threat-
ening DSS. It is proposed that proinflammatory cytokines
and chemokines as a result of DENV infection form a ‘‘cyto-
kine storm’’ and lead to increased vascular permeability.
DENV infection in human affects a variety of organ
functions, and viral nucleic acids and proteins have been
detected in many tissues (Acosta et al., 2014). As such,
many different infection systems can be used to model
different aspects of DENV infection, although each has its
limitations. Laboratory animals by and large sustain only
low levels of infection and do not recapitulate natural
disease progression (Rothman, 2011). Primaryhuman cells,
including monocytes, macrophages, hepatocytes, and
endothelial cells, represent the most physiologically rele-
vantmodel in vitro. However, these cells are limited in sup-
ply andoftenexhibit significantdonor-to-donor variability.
The monocyte-lineage cells are considered a major target
of DENV in vivo (Blackley et al., 2007; Wu et al., 2000;Stem Cell Repo
This is an open access article under the CPham et al., 2012; Jessie et al., 2004), but DENValso infects
liver in vivo (Halstead, 2007; Povoa et al., 2014; Balsitis
et al., 2009). The clinical manifestations of DENV infection
of liver range from asymptomatic mild liver function ab-
normality in most cases to acute liver failure. In vitro,
DENV has been demonstrated to infect hepatoma cell lines
(Marianneau et al., 1997; Cabrera-Hernandez et al., 2007;
Hilgard and Stockert, 2000; Heaton and Randall, 2010) as
well as primary human hepatocytes (PHHs) (Suksanpaisan
et al., 2007), but these cells are either genetically abnormal
or not universally accessible. The stem cell-derived, differ-
entiated human hepatocyte-like cells (HLCs/DHHs/iHeps)
have been shown to support productive infection by
HCV (Wu et al., 2012; Schwartz et al., 2012; Roelandt
et al., 2012) and hepatitis B virus (HBV) (Shlomai et al.,
2014). In the current study, we apply the HLC model to
study the interactions between DENV and hepatic cells.
We demonstrate that pluripotent stem cells are refractory
to DENV infection but that DENV can efficiently and pro-
ductively infect the HLCs. The permissiveness transition
correlates with the induction of putative DENV receptors.
The profound changes caused by DENV infection of
HLCs include stimulation of innate immunity, apoptosis,
and cytokine and chemokine induction, all of which reca-
pitulate important aspects of dengue-host interaction. In
addition, we found that DENV infection leads to a partial
dysregulation of hepatic functions, such as the downregu-
lation of essential components of the complement and
coagulation systems, which might be relevant to DENV
pathology. The HLCs thus represent a valuable stem cell-
based model for investigations into DENV-hepatic cell
interactions.rts j Vol. 7 j 341–354 j September 13, 2016 j ª 2016 The Author(s). 341
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Differentiation of Hepatocyte-like Cells from Human Pluripotent Stem Cells
(A) Schematic description of the four stages of hepatocyte differentiation.
(B) Undifferentiated hESCs. hESCs were positive for NANOG, SOX2, OCT4, and SSEA4 and maintained in the pluripotent state.
(C) Induction of definitive endoderm. The expression of specific marker genes SOX17 and CXCR4 were induced in hESC-derived definitive
endoderm at day 3.
(D) Hepatic specification. At day 6 after differentiation, the differentiated hepatic progenitors were AFP and CK19 double-positive and
homogenously expressed the hepatic gene HNF4A.
(E) Maturation of hepatic progenitors into hepatocyte-like cells. The HLCs underwent functional maturation from day 7. At day 17, the
resulting cells expressed specific genes unique to hepatocytes, including AFP, ALB, A1AT, NTCP, and coagulation factor F5. Lipid droplets
were formed in these cells.
(F) Induction of genes preferentially expressed in the liver during differentiation. Heatmap of RNA-seq expression values (log10(1 + FPKM))
of the 291 RefSeq genes preferentially expressed (Liu et al., 2008) in liver at day 5, day 10, and day 12 of differentiation.
See also Table S1 and Figure S1. Scale bar, 50 mm.RESULTS
Differentiation of Human Pluripotent Stem Cells into
Hepatocyte-like Cells
A chemically defined differentiation protocol was used to
derive human HLCs from human pluripotent stem cells342 Stem Cell Reports j Vol. 7 j 341–354 j September 13, 2016(hPSCs) in vitro (Si-Tayeb et al., 2010; Touboul et al.,
2010), as shown in Figure 1A. The undifferentiated hu-
man embryonic stem cells (hESCs) expressed pluripotent
marker genes, including octamer-binding transcription
factor 4 (OCT4), NANOG, sex determining region Y-box 2
(SOX2), and stage-specific embryonic antigen 4 (SSEA4)
(Figure 1B). Upon differentiation to definitive endoderm,
the endodermic markers sex determining region Y-box 17
(SOX17) and chemokine (C-X-C motif) receptor type 4
(CXCR4) started to express (Figure 1C). Hepatic specifi-
cation resulted in a hepatic progenitor population that
expressed a-fetoprotein (AFP), cytokeratin 19 (CK19), and
hepatocyte nuclear factor 4a (HNF4A) (Figure 1D). These
cells were further differentiated toward the hepatic lineage
and started to adopt distinct hepatocyte morphology,
including defined and canaliculated borders and a polyg-
onal appearance (Figure S1A). Many more liver-specific
genes such as albumin (ALB), a1-antitrypsin (A1AT), so-
dium/taurocholate cotransporting polypeptide (NTCP),
and coagulation factor V (F5) were also expressed in the
HLCs (Figure 1E). These cells also gained the ability to
form lipid droplets (Figure 1E), a site of particle assembly
for several viruses (Miyanari et al., 2007; Samsa et al.,
2009). In the same way, human induced pluripotent stem
cells (iPSCs) were differentiated along the hepatic lineage
with each stage expressing the specificmarkers (Figure S1B).
RNA-sequencing (RNA-seq) analysis showed that the
expression levels of many liver-specific genes were upregu-
lated in day-12 compared with day-5 cells (Figure 1F and
Table S1), and thus were the core hepatic transcription fac-
tors (Figure S1C). Together, these data are consistent with
efficient hepatic differentiation in vitro.
The Hepatocyte-like Cells Express TAM3 and Support
Productive Infection by Dengue Virus
Whether the HLCs are permissive for DENV infection has
not been tested previously. We exposed the stem cells
and their progeny cells during the course of the hepatic dif-
ferentiation to dengue virus serotype 2 (DENV2) for 48 hr
and then lysed the cells for detection of intracellular
expression of dengue antigens. The signal for DENV NS3
and, to a lesser extent, capsid, became detectable at day 6
post differentiation, indicating successful infection of
these cells (Figure 2A). The infection efficiency steadily
increased in the subsequent days until day 11 when both
the NS3 and the capsid signal reached saturation (Fig-
ure 2A). Immunostaining confirmed that the percentage
of DENV NS3-positive cells increased from day 6 to day
10 (Figure 2B). At day 11, almost all HLCs can be infected
by DENV at a high MOI. In contrast, hPSCs were refractory
to DENV infection (Figure S2A). Furthermore, iPSC-derived
HLCs were permissible to DENV infection (Figure S2B). The
infection could be suppressed by known inhibitors of
DENV infection such as interferon-a2a (IFN-a2a), chloro-
quine (CQ), and mycophenolic acid (MPA) (Figures 2C
and 2D), indicating that the detected NS3 expression repre-
sents authentic viral infection and replication. Persistent
replication of DENV in the infected HLCs was indicated
by the continuous secretion of NS1 into the cell culturemedium after repeated wash and medium change cycles
(Figure 2E). Virus production from the infected HLCs was
demonstrated by using supernatant from the infected cells
to infect themosquito cell line C6/36, the natural host cells
in mosquito, and virus titration (Figures 2F and 2G). Anal-
ysis of the RNA-seq data revealed that the expression of a
TAM family phosphatidylserine receptor, AXL receptor
tyrosine kinase (AXL or TAM3), as well as its ligand protein
S (PROS), were upregulated in HLCs compared with day-5
cells (Figure 2H), consistent with the report that these
proteins play important roles in binding dengue virions
and mediating entry into multiple cell types, including he-
patocytes (Meertens et al., 2012). In addition, claudin-1
(CLDN1), which interacts with prM/M protein of DENV
and has been implicated in DENV entry (Che et al.,
2013), was also upregulated (Figure 2H).
Dengue Virus Infection of the HLCs Induces Innate
Immune Response that Limits Virus Spread
To determine whether infection triggered IFN production
and signaling in these cells, we performed RNA-seq on
HLCs with or without DENV infection. A robust induction
of antiviral proteins by DENV infection was detected, and
many genes involved in the IFN pathway were remarkably
upregulated (Figure S3A). Immunoblots to detect selected
IFN-stimulated genes (ISGs) confirmed the strong induc-
tion of IFN-induced transmembrane protein 1 (IFITM1)
and ubiquitin-specific peptidase 18 (USP18) in the HLCs
upon infection (Figure 3A). Interestingly, the expression
of IFITM1, but not that of USP18, was elevated in the undif-
ferentiated cells to a comparable level with what could be
induced by IFN (Figure 3A). We next determined whether
IFN activation and signaling played a role in limiting
DENV infection and spread in these cells. A Janus kinase
inhibitor (JAKi) completely abolished the induction of
IFITM1 by DENV infection and allowed robust expression
of DENV NS3, even in the presence of exogenous IFN (Fig-
ure 3B). An inhibitor of TANK-binding kinase 1 (TBK1), a
key kinase in IFN activation pathway, partially inhibited
DENV-mediated IFITM1 induction, but only did so in the
absence of exogenous IFN (Figure 3B). These results indi-
cate that the complete IFN network is activated in these
HLCs. Consistent with the hypothesis that IFN signaling
is responsible for the observed self-limiting infection, treat-
ment with JAKi resulted in rapid spreading of infection to
100% of the HLCs (Figures 3C and 3D). While IFN produc-
tion can protect the uninfected cells in a paracrine fashion,
it has been reported that DENV can inhibit IFN signaling
via a variety ofmechanisms in the infected cells.We indeed
observed that despite the robust induction of ISGs in the
uninfected cells, the expression of the IFITM family pro-
teinswas reduced in the infected cells (Figure S3B), support-
ing an efficient role of DENV in blocking IFN signaling. WeStem Cell Reports j Vol. 7 j 341–354 j September 13, 2016 343
Figure 2. HLCs Supported Persistent and Productive Infection of DENV
(A) DENV2 infection of HLCs in a differentiation stage-dependent manner. The hESCs (day 0) and differentiated cells at various differ-
entiation stages from day 1 to day 13 were inoculated with DENV2 (strain 16681) at an MOI of 2 for 48 hr, and cell lysates were collected for
western blotting.
(B) Immunostaining analysis of DENV2-infected HLCs. hESCs (day 0), definitive endoderm (day 3), hepatic progenitors (day 6), and HLCs
(day 10) were infected by DENV2 as described above. Cell were fixed and stained with anti-NS3 antibody. Scale bar, 50 mm.
(C) DENV2 infection was blocked in HLCs by inhibitors. HLCs at day 15 after differentiation were pretreated with IFN-a2a (1,000 U/mL),
MPA (1 mM), CQ (5 mg/mL), or DMSO (0.1%, v/v) for 8 hr, then subjected to DENV2 infection as described above.
(D) qRT-PCR analysis of DENV RNA levels. Cells were treated as described above. The relative DENV RNA level in each sample was normalized
to DMSO-treated samples.
(E) Persistent replication of DENV2 in HLCs. Day-15 HLCs were exposed to DENV2 for 6 hr before the cells were stringently washed. NS1
protein in the supernatant collected every 24 hr after infection was measured by ELISA assay.
(F) DENV2 particles released from HLCs efficiently infected C6/36 cells. HLCs at day 15 were infected with DENV2 at an MOI of 2 for 6 hr. The
inoculum was then removed and the cells washed stringently with PBS five times before the fresh medium was added. The supernatants
were collected every 24 hr from day 16 to day 20. After each change of the spent medium, cells were washed stringently as described above.
Each medium supernatant was added to naive C6/36 cells and incubated for 24 hr. Cells were then lysed and subjected to western blotting
analysis. DENV2 derived from C6/36 cells was used as a positive control.
(G) Virus titration. Virus titers were calculated in the above supernatants collected at 24, 48, and 72 hr post infection.
(H) Upregulation of DENV entry factors during the differentiation process. Total RNA from differentiated cells at the indicated days were
extracted and subjected to real-time qRT-PCR to measure the cellular expressions of AXL, HAVCR1, PROS, and CLDN1. GAPDH was used as the
reference and its expression was set as 1. All the genes were normalized to GAPDH to obtain their relative gene-expression ratio.
Three independent experiments were performed. Data are presented as mean ± SD. p Values were calculated by Student’s t test: *p < 0.05,
**p < 0.01, ***p < 0.001. See also Figure S2.
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further compared the HLCs with a hepatoma cell line, Huh
7.5, to evaluate the difference in DENV infection efficiency
and immune response. As shown in Figure 3E, DENV infec-
tion did not spread to the whole cell population of the
HLCs. In contrast, the virus infection rate and virus titer
increased rapidly after DENV infectedHuh 7.5 cells (Figures
3E–3G). Furthermore, no IFITM1 expression was induced
in Huh 7.5 cells upon DENV infection (Figure 3H), suggest-
ing a deficiency in innate immunity in this hepatoma cell
line.
Dengue Virus Infection Activates NF-kB Pathway and
Triggers Proinflammatory Cytokine Expression
We observed that DENV infection led to significant accu-
mulation of phosphorylated RELA/p65, the main activator
of the nuclear factor kB (NF-kB) pathway, in the entire
population regardless of the infection status of individual
cells (Figures 4A and 4B). These suggested that the NF-kB
pathway was activated not only by DENV itself, but in a
paracrine fashion, such as tumor necrosis factor a (TNF)
secretion. Furthermore, DENV infection of the HLCs also
resulted in increased reactive oxygen species (ROS) produc-
tion (Figure 4C), which, together with NF-kB activation,
can lead to the expression of a large number of chemokines
and proinflammatory cytokines, such as TNF, interleukin-6
(IL6), IL8, IL10, and IL12 (Figure 4D).
IFN Signaling Counteracts DENV-Induced Apoptosis
of the HLCs
DENV infection of the HLCs led to cell death that showed
characteristics of apoptosis, including morphological
changes (Figure S4A), positivity in TUNEL assay (Figures
5A, S4B, and S4C), and the cleavage of caspase-3 (CASP3)
and poly(ADP-ribose) polymerase (PARP), a hallmark event
of apoptosis (Figure 5B). Several important pro-apoptotic
genes, including TNF and Fas cell surface death receptor
(FAS), were greatly upregulated by DENV infection (Fig-
ure S4D). Interestingly, cell death was dramatically exacer-
bated when the infected cells were also treated with JAKi.
Under infection conditions of high MOI (MOI = 5 or
greater), virtually all HLCs became infected within 24 hr,
regardless of the presence or absence of JAKi. Without the
inhibitor, cell deaths occurred in 25%–30% of cells but
DENV-positive cells persisted up to 144 hr in culture,
when the HLCs almost reached their normal lifespan in
culture (Figure 5C, top panels). In the presence of JAKi,
however, massive cell death occurred 72 hr after infection
and no cells survived past 96 hr after infection (Figure 5C,
bottom panels). JAKi alone in the absence of DENV
infection did not cause cell death (Figure 5D). These data
strongly suggest that DENV-infection-triggered apoptosis
is counterbalanced by IFN signaling activation. Indeed,
the cleavage of CASP3 and PARP became undetectable after120 hr post infection, even though these cells were still
productively infected with DENV (Figure 5E). Consistent
with the hypothesis, DENV infection induced the rapid
cell death of Huh 7.5 cells within 96 hr, compared with
the HLCs (Figure 5F).DengueVirus Infection Leads to Partial Loss ofHepatic
Features In Vitro
We further investigated the effect of DENV infection on
hepatic gene expression. Downregulation of E-cadherin
and b-catenin was observed in the infected cells (Fig-
ures S5A and S5B), suggesting the loss of adherens junc-
tions. To determine whether specific hepatic functions
were affected, we analyzed genes that preferentially ex-
pressed in the liver from the RNA-seq dataset. In addition
to a general reduction ofmany liver-specific genes in the in-
fected cells (Figure 6A), we also observed a downregulation
of several coagulation factors and a component of the com-
plement system (Figure S5C). Immunostaining confirmed
that ALB and F5 levels were reduced in the infected cells
(Figure 6B), whereas those of other hepatic proteins such
as cytokeratin 18 (CK18) andHNF4Awere not affected (Fig-
ures S5D and S5E), indicating that the downregulation of
ALB and F5 was not a result of non-specific inhibition of
protein synthesis by DENV.All Four Serotypes of DENV Can Downregulate ALB
and F5 in Primary Human Hepatocytes
To determine whether the downregulation of ALB and F5
by DENV also occurred in PHHs, we performed parallel in-
fections of HLCs and PHHs using high MOI. As shown in
Figure 6C, substantial reduction of bothALB and F5 protein
levels were seen in both infected HLCs and PHHs. We also
investigatedwhether other serotypes of DENV can downre-
gulate these liver proteins in theHLCs and PHHs. As shown
in Figure 6D, infection by isolates representing all different
serotypes efficiently downregulated ALB and F5 expres-
sion, suggesting that this is a conserved function of DENV.DISCUSSION
Human HLCs derived from pluripotent stem cells are
permissive to infection by hepatotropic viruses, including
HCV and HBV. Interestingly, the SEC14L2 gene, an essen-
tial host factor for supporting the replication of wild-
type, unadapted HCV genomes, was induced during the
hepatic differentiation (data not shown) but not expressed
in the hepatoma cell line Huh 7.5 cells (Saeed et al., 2015).
This difference may account for the ability of the HLCs
to support infection by HCV patient serum (Wu et al.,
2012; Saeed et al., 2015). Here we demonstrate that
these cells also support productive infection and persistentStem Cell Reports j Vol. 7 j 341–354 j September 13, 2016 345
Figure 3. Interferon Response Induced by DENV Infection in HLCs
(A) Upregulation of IFITM1 and USP18 upon DENV2 infection. The hESCs (day 0) and differentiated cells from day 1 to day 11 were
inoculated with or without DENV2, and cell lysates were collected 48 hr post infection for western blotting. IFN-a2a-treated cells at day 12
were used as a positive control.
(B) Inhibition of IFN signaling pathway enhanced DENV2 infection. HLCs at day 15 were pretreated with DMSO (0.1%), JAK inhibitor
(1 mM), or TBK1 inhibitor (2 mM) for 3 hr, followed by incubation with or without IFN-a2a (1,000 U/mL) for 8 hr. Cells were then infected
with DENV2 at an MOI of 0.3 for 48 hr. Cell lysates were collected for western blotting.
(C) Inhibition of IFN signaling resulted in the spread of DENV2. Cells were treated as described above, and infected by DENV2 at an MOI of
0.01 for 72 hr. Cells were fixed and stained for immunostaining. Scale bar, 50 mm.
(D) Statistical analysis of the percentage of DENV infection. HLCs were pretreated with DMSO, JAKi, and IFN as described above, then
infected by DENV2 at an MOI of 0.5 for 48 hr. The percentage of DENV infection in each sample was analyzed by immunostaining assay.
(legend continued on next page)
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Figure 4. DENV Infection Activated NF-kB Signaling Pathway
(A) Phosphorylated RELA/p65 entered the nuclei after DENV2 infection. HLCs were infected by DENV2 at an MOI of 2 for 48 hr and then
subjected to staining. Scale bar, 50 mm.
(B) Statistical analysis of the ratio of phospho-NF-kB RELA/p65 positive cells in the whole population. Three independent experiments
were performed. Data are presented as mean ± SD. p Values were calculated by Student’s t test: ***p < 0.001.
(C) DENV2 infection increased ROS production. HLCs were infected by DENV2 at an MOI of 2 for 48 hr during which time the cells were
treated with or without PDTC as an antioxidant (10 mM). General oxidative stress indicator was used to detect ROS production. Scale
bar, 50 mm.
(D) Transcriptional activation of cytokine and chemokine genes by DENV infection. Bar plot of log2(DENV2-treated/untreated) ratios of
RNA-seq expression values for cytokines and chemokines targeted by NF-kB signaling (http://www.bu.edu/nf-kb/gene-resources/
target-genes/). Bars are colored based on the significance of differential expression based on DESeq2. Note that some genes displayed
apparently large differences in expression levels, but lack enough sequencing reads to support a significant change in expression, and
these bars are colored black.replication of DENV. The timing of transition to viral
permissiveness during the hepatic differentiation differs
for the three viruses. For HCV, the transition required the
induction of a liver-specific microRNA, miR-122 (Wu
et al., 2012; Jopling et al., 2005), while HBV infection of
the differentiated HLCs correlated with the induction of
the HBV receptor, sodium taurocholate cotransporting
peptide (NTCP) (Shlomai et al., 2014; Yan et al., 2012).
Similar to the situation with HBV, transition to DENV
permissiveness correlated with the induction of DENV
entry factors, the TIM-TAM family of proteins and their
ligand, for hepatic cells (Meertens et al., 2012). Elucidating
gene-expression changes that are associated with the shift
to virus susceptibility during differentiation represents a(E–G) Comparison of virus infection between HLCs and Huh 7.5 cells. B
48 hr. Cell samples and the supernatants were collected every 24 hr f
virus titration (G). Cells were washed stringently before medium chan
(H) No induction of IFITM1 in Huh 7.5 cells upon DENV2 infection. C
24 hr post infection for western blotting.
Three independent experiments were performed. Data are presented as
**p < 0.01, ***p < 0.001. See also Figure S3.valuable approachwith the potential of identifying cellular
determinants that control viral infection. This approach is
especially attractive in the case of DENV because of the
extraordinarily broad tropism it exhibits in cell culture
(Acosta et al., 2014). In fact, hPSCs and the early progenies
are rare examples of cells that are refractory to DENV infec-
tion in vitro.
In the liver, hepatocytes are organized as polarized
epithelial cell layers to separate sinusoidal blood from the
secreted bile and perform hepatic functions, and specific
cell-cell junctions are required for the maintenance of the
polarized cell layers (Gissen and Arias, 2015). In some liver
diseases, these junctions and the polarity of hepatocytes
are affected. However, it is difficult to fully elucidate theoth HLCs and Huh 7.5 cells were infected by DENV2 at an MOI of 1 for
or immunostaining analysis (E), infection rate calculation (F), and
ge. Scale bar, 50 mm.
ells were treated as described above. Cell samples were collected at
mean ± SD. p Values were calculated by Student’s t test: *p < 0.05,
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Figure 5. Innate Immunity Protected HLCs from Massive Apoptosis Induced by DENV
(A) DENV2 infection led to apoptosis of HLCs. At 48 hr post DENV infection at an MOI of 2, HLCs were fixed for TUNEL assay. For the positive
control, 0.5 mM doxorubicin, as an apoptosis inducer, was incubated with HLCs for 24 hr. Scale bar, 50 mm.
(B) DENV2 infection resulted in PARP and CASP3 cleavage. HLCs at day 15 were pretreated with JAKi (1 mM) or Z-Vad (50 mM) for 3 hr,
followed by DENV2 infection as described above.
(C) Most of the DENV2-infected cells survived the infection. Day-15 HLCs were incubated with or without JAKi (1 mM) for 3 hr, then
subjected to DENV2 infection at an MOI of 5 for 144 hr. Cell samples were collected at different time points after infection for immu-
nostaining. Scale bar, 50 mm.
(D) The time course of apoptosis induced by DENV2. HLCs treated with or without IFN-a2a (1,000 U/mL) or JAKi (1 mM) were incubated
with or without DENV2 at an MOI of 5 for 144 hr as described above. Cell samples were collected every 24 hr and subjected to MTT assay.
Relative cell viability was calculated by comparing each sample with the mock.
(E) PARP and CASP3 cleavage during DENV2 infection. HLCs were infected by DENV2 at an MOI of 5 for 144 hr. Cell samples at different time
points were collected for western blotting.
(F) Comparison of cell death between HLCs and Huh 7.5 cells after DENV2 infection. Both HLCs and Huh 7.5 cells were infected by DENV2 at
an MOI of 5 for 96 hr. Cell samples were collected every 24 hr for MTT assay.
Three independent experiments were performed. Data are presented as mean ± SD. p Values were calculated by Student’s t test: *p < 0.05,
**p < 0.01, ***p < 0.001. See also Figure S4.
348 Stem Cell Reports j Vol. 7 j 341–354 j September 13, 2016
Figure 6. DENV Infection Inhibited the
Expression of ALB and F5
(A) Bar plot of log2(DENV2-treated/un-
treated) ratios of RNA-seq expression values
for the 291 RefSeq genes preferentially
expressed in liver (Liu et al., 2008). RNA-
seq data were analyzed in the same way as
described in Figure 4.
(B) Immunostaining of DENV2-infected
HLCs. HLCs at day 15 were infected by DENV2
at an MOI of 2 for 72 hr. Cells were fixed
for immunofluorescence analysis. Scale bar,
50 mm.
(C) ALB and F5 expression were down-
regulated in both the HLCs and PHHs after
DENV2 infection. PHHs and HLCs were in-
fected by DENV2 at an MOI of 5 for 72 hr and
then subjected to western blotting.
(D) Other three serotypes of DENV reduced
F5 and ALB expression in the HLCs and
PHHs. HLCs and PHHs were infected by DENV
type 1-Hawaii, DENV type 3-MK-594-87,
DENV type 4-H241, and DENV type 4-D85-
019 as described above. Cell lysates were
collected for western blotting.
See also Figure S5 and Table S2.pathophysiological features of hepatocytes using hepa-
toma cell lines because hepatocellular epithelial to mesen-
chymal transition and degeneration are common events
in hepatocellular carcinoma progression, which result in
the loss of epithelial features and some hepatic functions
(van Zijl et al., 2009). In the case of DENV infection, it is
has been reported that DENV can damage hepatocytes
and disrupt liver functions, leading to elevations of
serum bilirubin and transaminases, prolonged prothrom-
bin time, and reduced serum albumin level (Huy et al.,
2013; Roy et al., 2013; Samanta and Sharma, 2015). In
our study, we utilized stem cell-derived HLCs to investigate
the interactions between DENV and hepatocytes andobserved downregulation of albumin, several coagulation
factors, and a component of the complement pathway by
DENV infection. These virus-induced changes in hepatic
features may contribute to the effect of DENV on liver
in vivo. The precise mechanism of the direct downregula-
tion of these genes remains unclear at this time.
DENV infection activates an antiviral response in vitro
and in vivo (Green et al., 2014). Our results showed
that many reported anti-DENV ISGs, including IFITM1,
IFTM3, IRF1, IRF7, and IFI6 (Schoggins et al., 2012; Brass
et al., 2009), were highly increased in the DENV-treated
HLCs, which probably is the main reason why DENV
infection of hepatic cells is self-limiting. In vivo, the IFNStem Cell Reports j Vol. 7 j 341–354 j September 13, 2016 349
response generated by the hepatic cells is likely comple-
mented by similar responses from resident immune cells
in the liver; in fact, IFN secreted from infected immune
cells can also trigger IFN signaling in the hepatocytes and
protect liver from massive infection. Together, these data
may help explain the rareness of acute liver injuries in
DENV infection.
DENV has also been shown to counteract IFN signaling
in the infected cells, mainly through the expression of
NS5 and NS4B (Munoz-Jordan et al., 2005; Ashour et al.,
2009; Morrison et al., 2013). We indeed observed lessened
ISG induction in the infected cells but not in the unin-
fected cells in the same virally exposed population. Consis-
tent with these results, we found that although the infec-
tion of HLCs was normally self-limiting when a low MOI
was used, virtually all cells could be infected if a high (>5)
MOI was used in the initial inoculation, as no viral spread
was needed in this case to infect all the cells and the IFN
response was not able to clear the infection once it had
been established. As reduced viral load generally correlates
with lessened disease severity (Marques et al., 2015), thera-
peutic strategies aiming at reducing viral load early may
better harness the benefit of host IFN response to thwart
disease progression.
A ‘‘cytokine storm’’ triggered by DENV is thought to be
the major event of DENV pathogenesis (Guzman and Har-
ris, 2015). Several cytokines that have been proposed to be
associated with plasma leakage, including TNF, IL-6, IL-8,
IL-10, and IL-12 (Guzman and Harris, 2015), were dramat-
ically upregulated in HLCs by DENV infection. Activa-
tion of an inflammatory response via the cellular NF-kB
pathway by the secreted viral protein NS1 is one underly-
ing mechanism of the cytokine activation (Modhiran
et al., 2015; Beatty et al., 2015; Silva et al., 2011). We
observed a remarkable upregulation of mRNA levels of
TNF and CD137 (TNFRSF9), the major signal and receptor
for the canonical NF-kB pathway. The expression of CD40
gene was also induced by DENV infection, but its ligand,
CD40LG, was not expressed in these hepatic cells, suggest-
ing that the non-canonical NF-kB pathway is not activated
in the HLC system. Because the TNF gene can also be stim-
ulated by type I IFN, its induction by DENV infection may
represent the crosstalk before the cellular antiviral response
and the inflammatory response at the tissue level. Further-
more, ROS induction by DENV infection can also influence
the outcome of the NF-kB pathway activation (Morgan and
Liu, 2011; Olagnier et al., 2014). Finally, direct activation of
NF-kB pathway by DENV protease has also been reported.
In this case, the DENV protease induces the degradation
of NF-kB inhibitors IkBa and IkBb via cleavage (Lin et al.,
2014). Regardless of the mechanism of the initial acti-
vation, these signal molecules likely elicit an amplified
response through both autocrine and paracrine pathways.350 Stem Cell Reports j Vol. 7 j 341–354 j September 13, 2016The nuclear translocation of RELA/p65 was indeed de-
tected in all the cells including the uninfected cells. Unlike
the IFN signaling and ISG induction, we did not observe
any evidence of DENV proteins interfering with NF-kB
signaling in the infected cells. The unabated activation of
NF-kB pathway and the release of cytokines from hepato-
cytes, either infected or exposed to soluble signals (NS1, cy-
tokines) produced by infected blood cells, likely contribute
to the inflammatory aspects of dengue pathology.
Induction of apoptosis of immune cells following DENV
infection is a common feature in vivo. However, it has not
been well documented whether DENV causes massive
apoptosis of hepatocytes in the same way. We observed
rapid cell death and CASP3 activation early in the infection
time course. However, a population of the infected cells
eventually survived and showed no signs of cleavage of
CASP3 or PARP, but only when IFN signaling was not
completely blocked. Together, these data point to an anti-
apoptotic role of IFN signaling during DENV infection of
the HLCs, such as the one reported for IFI6 in DENV-in-
fected endothelial cells (Qi et al., 2015). In addition, viral
protein-induced autophagy has been proposed as an addi-
tional mechanism for protecting the infected epithelial
cells from apoptosis (McLean et al., 2011). In vivo, the
infected hepatocytes may also be cleared by antibody-
dependent cell-mediated cytotoxicity and T cell-mediated
cytotoxicity through DENV antigen (such as NS1) dis-
played on the cell surface. Despite all of these factors, the
strong capacity of regeneration of the liver likely contrib-
utes to the rareness of acute liver failure.
DENV, as one of the most widespread vector-borne vi-
ruses, infects millions of people each year worldwide. How-
ever, no clinically approved drugs are yet available against
DENV. There is an urgent need to develop effective anti-
DENV drugs for such treatment. In this study we tested
IFN-a2a, chloroquine, and mycophenolic acid for their
ability to inhibit DENV infection in our in vitro system.
IFN, as a well-established antiviral cytokine, can block
several RNA and DNA viruses at different stages from viral
entry to release. Both chloroquine and mycophenolic
acid have been shown to inhibit replication of DENV in
the laboratory tests (Farias et al., 2013; Diamond et al.,
2002). Consistent with previous studies, all of these inhib-
itors reducedDENV infection inHLCs at various levels, sug-
gesting that our in vitro system may have potential utility
for anti-DENV drug screening efforts.
In summary, we demonstrate that DENV can produc-
tively infect human HLCs derived from PSCs and pro-
duce in vitro phenotypes that reflect pathophysiologically
relevant aspects of DENV-host interaction. These HLCs,
which transit from refractory to permissive for DENV infec-
tion under defined growth conditions, are also useful
tools for dissecting the molecular determinants of DENV
susceptibility and the identification of new drug targets
for this important human pathogen. Finally, coupling
genome-editing technologies, patient-specific iPSCs, or
both with the HLC-DENV system can enable research
into the effect of host genetics on DENV infection and
pathogenesis.EXPERIMENTAL PROCEDURES
Cells and Viruses
hESC line H9 (WA09) and iPSC line iPS DF19-9-11T.H were ob-
tained fromWiCell Research Institute and propagated onMatrigel
(BD Biosciences)-coated plates in mTeSR1medium (Stemcell Tech-
nologies). Freshly isolated PHHs (Life Technologies) were main-
tained in William’s E media (Life Technologies) with Supplements
CM4000 (Life Technologies) in collagen-coated plates according to
the vendor’s instructions. Aedes albopictus cell clone C6/36 cells
(ATCC) were cultured in ATCC-formulated Eagle’s minimum
essential medium supplemented with 10% fetal bovine serum
(FBS) (Life Technologies). Huh 7.5 cells were provided by Charles
M. Rice and grown in DMEM (Life Technologies) with 10%
FBS. Three serotypes of DENV, including DENV type 1-Hawaii,
DENV type 3-MK-594-87, DENV type 4-H241, and DENV type
4-D85-019, were obtained from BEI Resources while DENV type
2-16681 was provided by Dr. Qianjun Li (University of Alabama).
All viruses were propagated in the C6/36 cells, and virus titers
were calculated by plaque assay on BHK21 cells (ATCC).
Differentiation of Human Pluripotent Stem Cells to
Hepatocyte-like Cells
To initiate differentiation, we collected hPSCs as small clumps from
a plate containing 80%–90% confluent stem cells and transferred
them into a 12-well plate coated with Matrigel at the confluence
of8%–10%in1mLofmTeSR1 ineachwell.After1–2daysof culture,
the medium was replaced by chemically defined basal me-
dium (DMEM/F12 [Mediatech]) containing 1.8% BSA [Millipore],
0.055 mM b-mercaptoethanol [Life Technologies], 13 L-glutamine
[Life Technologies], and 13 B27 supplement [Life Technolo-
gies]) supplemented with 100 ng/mL Activin A (R&D Systems),
25 ng/mLWnt 3a (R&D), 10 mM LY294002 (Sigma), and 10 ng/mL
fibroblast growth factor 2 (FGF2) (R&D) for 24 hr, followed by
100 ng/mL Activin A and 10 ng/mL FGF2 for 48 hr to specify defin-
itive endoderm (DE). DE was then induced into hepatoblast for
3 days using 1 mM retinoic acid (Sigma), 1 mM SB431542 (Sigma),
10 ng/mLBMP4 (R&D), and 10 ng/mL FGF2. Subsequently, hepatic
progenitors were differentiated for 6 days into early HLCs using
50 ng/mL HGF (Peprotech), 30 ng/mL FGF4 (Peprotech), and
50 ng/mL epidermal growth factor (EGF) (Peprotech), and further
differentiated using 10 ng/mL oncostatin M (R&D) for 3 days. The
HLCs were then grown in Clonetics HCM Hepatocyte Culture
Medium (Lonza) containing ‘‘Singlequots’’ omitting EGF and hy-
drocortisone with changes of fresh medium every 2 days.
DENV Infection
For DENV infection, cells were incubated with virus at the indi-
cated MOI for 6 hr before the medium was changed to the oneappropriate for the specific cell type and differentiation stage. At
48 or 72 hr post infection, cells were harvested for western blotting
or immunofluorescence analyses. The same amount of ‘‘spent’’me-
dium of uninfected C6/36 cells was added to the cells as the nega-
tive control. To inhibit DENV infection, we incubated 1,000 U/mL
IFN-a2a (Sigma), 1 mMmycophenolic acid (Sigma), 5 mg/mL chlo-
roquine (Sigma), or 0.1% DMSO (Sigma) with HLCs at day 15 for
8 hr before DENV infection. For the study of IFN response induced
by DENV, HLCs were treated with 0.1%DMSO (Sigma), 1 mM Janus
kinase inhibitor (JAKi) (Millipore), or 2 mMTANK-binding kinase 1
inhibitor (TBKi) (Millipore) for 3 hr. Cells were then infected with
DENV for 48 hr after incubation with or without 1,000 U/mL of
IFN-a2a for 8 hr. For the cell death assay, day-15 HLCs were pre-
treated with 1 mM JAKi or 50 mMZ-Vad (Santa Cruz Biotechnology)
for 3 hr, followed by DENV infection for 24–144 hr.RNA-Seq Data Analyses and Real-Time qRT-PCR
Total RNA were isolated from the differentiated cells of day 5, day
10, and day 12 with or without DENV infection by the miRNeasy
Mini kit (Qiagen) and then were sent to the Clinical Microarray
Core at UCLA and Genomics Research Center at the University
of Rochester for RNA-seq. The TruSeq RNA Sample Preparation
Kit V2 (Illumina) was used for next-generation sequencing library
construction as per manufacturer’s protocols. In brief, mRNA was
purified from 100 ng of total RNA with oligo-dT magnetic beads
and fragmented. First-strand cDNA synthesis was performed with
random hexamer priming followed by second-strand cDNA syn-
thesis. End repair and 30 adenylation was then performed on the
double-stranded cDNA. Illumina adaptors were ligated to both
ends of the cDNA, purified by gel electrophoresis, and amplified
with PCR primers specific to the adaptor sequences to generate am-
plicons of approximately 200–500 bp in size. The amplified li-
braries were hybridized to the Illumina single-end flow cell and
amplified using the cBot (Illumina) at a concentration of 8 pM
per lane. Single-end reads of 100 nt were generated for each sample
and aligned to the hg19 reference genome with Tophat2 (Kim
et al., 2013). Gene-level counts were calculated using reads with
alignment qualities >10 using featureCounts (Liao et al., 2014),
and differential expression was tested with DESeq2 (Love et al.,
2014). All the RNA-seq data were deposited in the NCBI Sequence
Read Archive with the accession number SRA: SRP078315. For RT-
PCR, the isolated total RNA was cleaned up by RNA Clean Kit
(Zymo) and converted to first-strand cDNA by SuperScript III kit
(Life Technologies). Real-time qPCR was then performed to
analyze the expression of DENV cofactors and receptors and
DENV RNA levels.NS1 ELISA
HLCs at day 15 were pretreated for 8 hr with or without
1,000 U/mL of IFN-a2a, followed by infection with DENV at an
MOI of 2 for 6 hr. The inoculum was then removed and the cells
washed stringently with PBS five times before fresh medium was
added. The supernatants were collected each day from day 16 to
day 21 formeasuring nonstructural protein 1 (NS1) in the superna-
tant, using a DENV NS1 Antigen ELISA Kit (Abnova). After each
change of the spent medium, cells were washed stringently as
described above.Stem Cell Reports j Vol. 7 j 341–354 j September 13, 2016 351
Immunofluorescence Staining
Cells grown on coverslips were fixed with 4% paraformalde-
hyde for 15 min, permeabilized with 0.1% Triton X-100 for
10 min, and blocked with PBGB (PBS containing 10% normal
goat serum, and 1% BSA) at room temperature for 2 hr.
Subsequently, cells were incubated with primary antibodies
at 4C overnight. After three washes with PBS, fluorescein
isothiocyanate or tetramethylrhodamine isothiocyanate-conju-
gated secondary antibody (Sigma) was added and incubated
at room temperature for 2 hr. The stained coverslips were
mounted in Vectashield medium (Vector Laboratories) after
three washes with PBS. Images were processed by Adobe
Photoshop.
MTTAssay
Cell viability wasmeasured by a colorimetric MTTassay (Life Tech-
nologies). Before the assay, the culturemediumwas changed to the
phenol red-free Clonetics HCMHepatocyte CultureMedium. After
incubation with MTT or DMSO, the optical absorbance was read
at 540 nm.
TUNEL Assay
Cell samples were fixed and stained using the In Situ Cell Death
Detection kit (Roche Applied Science) according to the manufac-
turer’s instructions. For the positive control, 0.5 mM doxorubicin
(Sigma) was incubated with HLCs for 24 hr.
ROS Detection
ROS production in the DENV-infected cells was detected
using CM-H2DCFDA General Oxidative Stress Indicator kit
(Life Technologies). After DENV infection of day-15 HLCs
for 48 hr, cells were washed twice with PBS and incubated
with 1 mM CM-H2DCFDA probe for 30 min at 37C. Following
three washes with PBS, oxidation of the probe in the DENV-
infected cells was detected by monitoring the increase in
green fluorescence with a fluorescence microscope. To inhibit
ROS production, we used 10 mM ammonium pyrrolidinedi-
thiocarbamate (PDTC) (Abcam) to treat HLCs during DENV
infection.
Statistical Analysis
All the data are presented as mean ± SD. Three independent exper-
iments were performed. p Values were calculated by two-tailed
Student’s t test: *p < 0.05, **p < 0.01, ***p < 0.001.
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